(Q33257886)

24 July 2017

1 reference

title

Genetics of antipsychotic treatment emergent weight gain in schizophrenia (English)

1 reference

24 July 2017

0 references

1 reference

Daniel J Müller

1

1 reference

24 July 2017

James L Kennedy

series ordinal

2

1 reference

24 July 2017

publication date

1 September 2006

1 reference

24 July 2017

1 reference

24 July 2017

volume

7

1 reference

24 July 2017

issue

6

1 reference

24 July 2017

page(s)

863-887

1 reference

Pharmacogenetics of antipsychotic-induced weight gain

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Negative v positive schizophrenia. Definition and validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Phenotype of schizophrenia: a review and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The Economic Burden of Schizophrenia in the United States in 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Schizophrenia and employment - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Barriers to employment for people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Do we still believe in the dopamine hypothesis? New data bring new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clinical implications of pharmacogenomics for tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight changes during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The association of weight gain and olanzapine plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Activation of Cdk2-pRB-E2F1 cell cycle pathway by repeated electroconvulsive shock in the rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine and body mass change.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine-induced weight gain predicts improvement in psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Changes in weight in patients receiving a tranquilizing drug

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight Changes With Schizophrenic Psychosis and Psychotropic Drug Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine-induced weight gain: prevalence and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Atypical antipsychotic induced weight gain: pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight change with atypical antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Psychiatric medication-induced obesity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Amisulpride is an "atypical" antipsychotic associated with low weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Years of life lost due to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Obesity as a disease: no lightweight matter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Obesity - an epidemic of the twenty-first century: an update for psychiatrists.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Reasons for switching between antipsychotics in daily clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Psychiatric medication-induced obesity: treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

A program for managing weight gain associated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight loss in overweight patients maintained on atypical antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Medical Consequences of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Genetics and pathophysiology of human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The genetic epidemiology of thinness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Brain regulation of food intake and appetite: molecules and networks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The gut and energy balance: visceral allies in the obesity wars

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

From lesions to leptin: hypothalamic control of food intake and body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The hardship of obesity: a soft-wired hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Central regulation of energy balance: inputs, outputs and leptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Obesity wars: molecular progress confronts an expanding epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Mechanisms of insulin resistance in humans and possible links with inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Genetic aspects of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Beyond energy balance: there is more to obesity than kilocalories

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

How can drug addiction help us understand obesity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Psychiatric medication induced obesity: an aetiologic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

An overview of the central control of weight regulation and the effect of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Plasma leptin and antipsychotic-induced body weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Ghrelin plasma levels during psychopharmacological treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

A prospective study of serum ghrelin levels in patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine's effects on body weight and resting metabolic rate: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The implications of weight changes with antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight gain with antipsychotic drugs: the role of the 5-HT2C receptor (HTR2C) and other genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The sympathetic nervous system and obesity: role in aetiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Brown adipose tissue: function and physiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The peripheral sympathetic nervous system in human obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The many faces of G protein signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Association of a human G-protein beta3 subunit variant with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Functional genomics approaches in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

G protein polymorphisms in hypertension, atherosclerosis, and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The genetics of human drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Pharmacogenetics in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Bodyweight gain with atypical antipsychotics. A comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

The Human Obesity Gene Map: The 2004 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

Serum leptin levels increase rapidly after initiation of clozapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.6.863

21 January 2018

Identifiers

DOI

10.2217/14622416.7.6.863

1 reference

release_bjmgv6xsq5ap7fxww6bfhgce2m

24 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bjmgv6xsq5ap7fxww6bfhgce2m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference